GlassScriptPhysician profile
Neil Lin Kao
NPI 1720089477
$22,697.58
in general payments reported to CMS, 2019-2025
44 companies · $4,642 in 2025
The $4,642 reported for 2025 was more than what 85% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,594 · 2020: $2,395 · 2021: $2,257 · 2022: $2,157 · 2023: $3,149 · 2024: $3,503 · 2025: $4,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,195.58 |
| Travel and Lodging | $1,099.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,071.62 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $2,444.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,629.51 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $1,548.55 | 2019-2025 | |
| Alk-Abello, INC | $1,544.00 | 2019-2021 | |
| Csl Behring | $1,368.56 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Pfizer INC. | $1,101.49 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,053.74 | 2019-2023 | |
| Shionogi INC | $965.87 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $879.40 | 2019-2025 | Dupixent |
| Abbvie INC. | $761.34 | 2022-2025 | |
| Genentech USA, INC. | $566.75 | 2019-2025 | Xolair |
| Octapharma USA, INC. | $455.41 | 2021-2025 | Panzyga, Cutaquig |
| Leo Pharma INC. | $355.90 | 2022-2025 | Adbry, Anzupgo |
| Optinose US, INC. | $332.24 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $330.12 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Grifols USA, LLC | $289.76 | 2019-2025 | Xembify |
| Hospira, INC. | $243.08 | 2021-2024 | |
| Mylan Specialty L.P. | $240.43 | 2019-2020 | |
| Covis Pharma Gmbh | $200.29 | 2021-2022 | |
| Amgen INC. | $182.31 | 2022-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $181.83 | 2022-2025 | Ryaltris |
| Kaleo, INC. | $166.97 | 2019-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $125.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.20 | 2020-2024 | Spiriva Respimat |
| Galderma Laboratories, L.P. | $72.20 | 2024-2025 | Nemluvio |
| Aytu Biopharma, INC. | $58.05 | 2020-2024 | Karbinal |
| Ars Pharmaceuticals Operations, INC. | $56.27 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $52.40 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $50.66 | 2023 | Orladeyo |
| Pharming Healthcare, INC. | $48.05 | 2024 | Ruconest |
| Lilly USA, LLC | $46.36 | 2024-2025 | Ebglyss |
| Aimmune Therapeutics, INC. | $39.47 | 2021-2022 | |
| Shire North American Group INC | $29.60 | 2019 | |
| Circassia INC. | $28.34 | 2019 | |
| Genentech, INC. | $27.42 | 2019 | |
| Eyevance Pharmaceuticals LLC | $23.69 | 2021 | |
| Organon LLC | $22.34 | 2025 | |
| X4 Pharmaceuticals, INC. | $16.39 | 2025 | Xolremdi |
| Bio Products Laboratory USA, INC. | $11.67 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Kao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.